Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer

Phase 3 Completed 174 enrolled UNICANCER

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the benefit of adding docetaxel-5 fluorouracile (D-5FU) regimen after pre-operative epirubicin-cyclophosphamide (EC) and loco-regional treatment in inflammatory breast cancer (IBC).

Timeline

Start: 2000-10
Primary completion: 2012-12
Completion: 2015-01

Publications

Results Goncalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, Fabbro M, Lerebours F, Lotz JP, Linassier C, Dohollou N, Eymard JC, Leduc B, Lemonnier J, Martin AL, Boher JM, Viens P, Roche H. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Ann Oncol. 2015 Aug;26(8):1692-7. doi: 10.1093/annonc/mdv216. Epub 2015 May 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	85 mg/m2	—
Background	Cyclophosphamide	Other / unclassified	4000 mg/m2	—
Background	Epirubicin	Small molecule	150 mg/m2	—

Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer

Summary

Timeline

Publications

Drugs

Indications